Holen Sie sich die Stockscreener-App
1.95
1.04%
0.02
Schlusskurs vom Vortag:
$1.93
Offen:
$1.92
24-Stunden-Volumen:
30,488
Relative Volume:
0.29
Marktkapitalisierung:
$88.63M
Einnahmen:
$134.00K
Nettoeinkommen (Verlust:
$-9.93M
KGV:
-5.7353
EPS:
-0.34
Netto-Cashflow:
$-6.72M
1W Leistung:
+4.84%
1M Leistung:
+4.84%
6M Leistung:
-10.96%
1J Leistung:
+21.12%
1-Tages-Spanne:
$1.9153
$1.98
1-Wochen-Bereich:
$1.9153
$2.35
52-Wochen-Spanne:
$1.41
$2.79
Entera Bio Ltd Stock (ENTX) Company Profile
Firmenname
Entera Bio Ltd
Sektor
Branche
Telefon
972-2-532-7151
Adresse
KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM
Vergleichen Sie ENTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENTX
Entera Bio Ltd
|
1.95 | 87.72M | 134.00K | -9.93M | -6.72M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-03-22 | Eingeleitet | Aegis Capital | Buy |
Entera Bio Ltd Aktie (ENTX) Neueste Nachrichten
Is Entera Bio Ltd. a good long term investmentConsistent double returns - jammulinksnews.com
What drives Entera Bio Ltd. stock priceMaximize returns with effective portfolio management - jammulinksnews.com
What are analysts’ price targets for Entera Bio Ltd. in the next 12 monthsUnlock your portfolio’s hidden potential - jammulinksnews.com
What is the dividend policy of Entera Bio Ltd. stockInvest confidently with professional guidance - jammulinksnews.com
How strong is Entera Bio Ltd. company’s balance sheetAchieve consistent double-digit growth - jammulinksnews.com
Does Entera Bio Ltd. stock perform well during market downturnsUnstoppable trading performance - jammulinksnews.com
How does Entera Bio Ltd. compare to its industry peersUnlock powerful market analysis and alerts - jammulinksnews.com
Is Entera Bio Ltd. a growth stock or a value stockInvest in high-yield stocks with confidence - jammulinksnews.com
What makes Entera Bio Ltd. stock price move sharplyFree Community Verified Stock Suggestions - Newser
Multi factor analysis applied to Entera Bio Ltd.Breakout Monitoring with Momentum Analysis - Newser
Sentiment analysis tools applied to Entera Bio Ltd.Stock Portfolio Risk and Return Analysis - Newser
How Entera Bio Ltd. stock performs during market volatilityProfitable Trading Blueprint with Entry Zones - Newser
How to forecast Entera Bio Ltd. trends using time seriesBear Market Safe Zone Technical Analysis - Newser
Entera Bio (ENTX) Projected to Post Earnings on Friday - Defense World
When is the best time to buy Entera Bio Ltd. stockHigh Return Trade Roadmap with Setup Filters - Newser
How volatile is Entera Bio Ltd. stock compared to the marketBest Dividend Tracker For Every Investor - jammulinksnews.com
Why Entera Bio Ltd. stock attracts strong analyst attentionBuy Signal Forecast With Short-Term Data - Newser
Entera Bio Ltd. Stock (ENTX) Opinions on FDA Agreement for EB613 Endpoint - Quiver Quantitative
How did ENTX's revenue and expenses trend in Q4 2024? - AInvest
Is Entera Bio Ltd. stock reversal real or fakeEntry Zone Forecast for Momentum Trading - Newser
Entera Bio (NASDAQ:ENTX) Trading Up 10.8% – What’s Next? - Defense World
Entera Bio Receives FDA Agreement on BMD as Primary - GlobeNewswire
Entera Bio Ltd. Recovery Hinges on Volume BreakoutFast Entry High Potential Stock Alerts Triggered - metal.it
Entera Bio stock surges after FDA agrees on BMD endpoint for EB613 By Investing.com - Investing.com South Africa
Entera Bio stock surges after FDA agrees on BMD endpoint for EB613 - Investing.com Nigeria
FDA agrees to BMD endpoint for Entera’s oral osteoporosis drug By Investing.com - Investing.com South Africa
Entera Bio Advances EB613 with FDA Approval - TipRanks
FDA Agrees to BMD Endpoint for First Oral Osteoporosis Drug Phase 3 Trial | ENTX Stock News - Stock Titan
Is it the right time to buy Entera Bio Ltd. stockHigh-profit stock alerts - jammulinksnews.com
What is Entera Bio Ltd. company’s growth strategyDiscover stocks with explosive upside potential - jammulinksnews.com
Finanzdaten der Entera Bio Ltd-Aktie (ENTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.93%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):